Physician
OIG excluded
Naushad, Abdul
Naushad, Abdul was paid $60K by Medicaid between Jan 2018 and Mar 2020, across 6 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 38% of everything it billed.
33Billing provider infoNAUSHAD, ABDUL
POPLAR BLUFF, MO 63901
POPLAR BLUFF, MO 63901
33aNPI1972596757assigned 08/26/2005
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$60K
24GClaims1,344
24DCodes billed6
24AFirst – last monthJan 2018 – Mar 2020
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Missouri
Rank by total paid#11 of 24
Median peer was paid$27K
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
OIG exclusionListed on the federal exclusion list (06/20/2023).
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,129 | $49K | |
| 2019 | 194 | $11K | |
| 2020 | 21 | $317.80 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38% | 609 | 553 | $23K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 25% | 257 | 247 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 22% | 158 | 156 | $14K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 10.0% | 240 | 222 | $6K |
| 62323 | 3.8% | 15 | 13 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.6% | 65 | 65 | $975.23 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.